Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

Summary by AI BETAClose X

BioNTech and Bristol Myers Squibb announced interim Phase 2 data from the ROSETTA Lung-02 trial for pumitamig in combination with chemotherapy for advanced non-small cell lung cancer, showing a confirmed objective response rate of 57.1% in non-squamous and 68.4% in squamous subtypes, with higher rates of 63.6% and 72.7% respectively at a lower dose. The bispecific immunomodulator demonstrated encouraging anti-tumor activity across all PD-L1 expression levels, with a manageable safety profile and low discontinuation rates, supporting its advancement into Phase 3 development with two additional global Phase 3 trials currently enrolling.

Disclaimer*

UK 100

Latest directors dealings